UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 32

Sortiert nach

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

Journal for immunotherapy of cancer, 2021-03, Vol.9 (3), p.e002068

2021

Volltextzugriff (PDF)

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer

BMC cancer, 2023-07, Vol.23 (1), p.708-708, Article 708

2023

Volltextzugriff (PDF)

The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth

Molecular cancer therapeutics, 2013-06, Vol.12 (6), p.890-900

2013

Volltextzugriff (PDF)

Semantic Segmentation of High-Resolution Airborne Images with Dual-Stream DeepLabV3

ISPRS international journal of geo-information, 2022-01, Vol.11 (1), p.23

2022

Volltextzugriff (PDF)

Trial Outcome and Associative Learning Signals in the Monkey Hippocampus

Neuron (Cambridge, Mass.), 2009-03, Vol.61 (6), p.930-940

2009

Volltextzugriff (PDF)

Assessment of Segmentation Parameters for Object-Based Land Cover Classification Using Color-Infrared Imagery

ISPRS international journal of geo-information, 2018-11, Vol.7 (11), p.424

2018

Volltextzugriff (PDF)

Ganciclovir-resistant cytomegalovirus encephalitis in a hematopoietic stem cell transplant recipient

Journal of neurovirology, 2010-04, Vol.16 (2), p.174-178

2010

Volltextzugriff (PDF)

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer

Cancer discovery, 2017-06, Vol.7 (6), p.610-619

2017

Volltextzugriff (PDF)

CHAPTER 13 - Hsp90 Inhibitors in Clinic

Inhibitors of Molecular Chaperones As Therapeutic Agents, 2014, p.336-378

Avsar, Emin

2014

Volltextzugriff (PDF)

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2018-04, Vol.13 (4), p.576-584

2018

Volltextzugriff (PDF)

Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis

Leukemia & lymphoma, 2016-05, Vol.57 (5), p.1211-1214

2016

Volltextzugriff (PDF)

A first-in-human phase 1 study of the next-generation RET inhibitor, LOXO-260, in RET inhibitor refractory patients with RET-altered cancers (trial in progress)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS8595-TPS8595

2022

Volltextzugriff (PDF)

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

Clinical cancer research, 2021-12, Vol.27 (24), p.6666-6676

2021

Volltextzugriff (PDF)

Abstract CT089: Phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC)

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT089-CT089

2019

Volltextzugriff (PDF)

Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.8516-8516

2019

Volltextzugriff (PDF)

FP401EVALUATION OF RELATIONSHIP BETWEEN ANEMIA BODY COMPONENTS, NUTRITIONAL STATUSES AND QUALITY OF LIFE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT PREDIALYSIS STAGE

Nephrology, dialysis, transplantation, 2015-05, Vol.30 (suppl_3), p.iii203-iii204

2015

Volltextzugriff (PDF)

Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF- mutant colorectal cancer ( BRAFm CRC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.3544-3544

2016

Volltextzugriff (PDF)

Adenosine acting via A1 receptors, controls the transition to status epilepticus-like behaviour in an in vitro model of epilepsy

Neuropharmacology, 2004-09, Vol.47 (3), p.427-437

2004

Volltextzugriff (PDF)

Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.CT136-CT136

2015

Volltextzugriff (PDF)

A Phase 1b Dose-Escalation Study of Encorafenib (LGX818) and Cetuximab With or Without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer

Cancer discovery, 2017-03, Vol.7 (6), p.610-619

2017

Volltextzugriff (PDF)

Phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF -mutant colorectal cancer

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.3514-3514

2014

Volltextzugriff (PDF)

Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.7543-7543

2012

Volltextzugriff (PDF)

Trial Outcome and Associative Learning Signals in the Monkey Hippocampus

Neuron (Cambridge, Mass.), 2009-03, Vol.61 (6), p.930-940

2009

Volltextzugriff (PDF)

THE EFFECT OF JPEG COMPRESSION IN CLOSE RANGE PHOTOGRAMMETRY

International Journal of Engineering and Geosciences (IJEG), 2017-02, Vol.2 (1), p.35-40

2017

Volltextzugriff (PDF)

Hsp90 Inhibitors in Clinic

Inhibitors of Molecular Chaperones As Therapeutic Agents, 2013

2013

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(31)

Publikationsform

Sprache

Englisch
(32)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(13)
Humans
(7)
Oncology
(6)
Adult
(4)
Female
(4)
Male
(4)
Physical Sciences
(4)
Technology
(4)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(3)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)
Hematology
(3)
Mutation
(3)
Neurosciences
(3)
Neurosciences & Neurology
(3)
Accuracy
(2)
Aged
(2)
Aged, 80 And Over
(2)
Algorithms
(2)
Animals
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer

The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth

Semantic Segmentation of High-Resolution Airborne Images with Dual-Stream DeepLabV3

Trial Outcome and Associative Learning Signals in the Monkey Hippocampus

Assessment of Segmentation Parameters for Object-Based Land Cover Classification Using Color-Infrared Imagery

Ganciclovir-resistant cytomegalovirus encephalitis in a hematopoietic stem cell transplant recipient

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer

CHAPTER 13 - Hsp90 Inhibitors in Clinic

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer

Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis

A first-in-human phase 1 study of the next-generation RET inhibitor, LOXO-260, in RET inhibitor refractory patients with RET-altered cancers (trial in progress)

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

Abstract CT089: Phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC)

Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC

FP401EVALUATION OF RELATIONSHIP BETWEEN ANEMIA BODY COMPONENTS, NUTRITIONAL STATUSES AND QUALITY OF LIFE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT PREDIALYSIS STAGE

Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF- mutant colorectal cancer ( BRAFm CRC)

Adenosine acting via A1 receptors, controls the transition to status epilepticus-like behaviour in an in vitro model of epilepsy

Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer

A Phase 1b Dose-Escalation Study of Encorafenib (LGX818) and Cetuximab With or Without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer

Phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF -mutant colorectal cancer

Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC)

Trial Outcome and Associative Learning Signals in the Monkey Hippocampus

THE EFFECT OF JPEG COMPRESSION IN CLOSE RANGE PHOTOGRAMMETRY

Hsp90 Inhibitors in Clinic

Suchergebnisse filtern